Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Signal binding to membrane receptor tyrosine kinases (RTKs) activates an enzyme called a kinase. Learn how kinases initiate a signaling cascade that relays information to the nucleus.